12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Company News  |  Deals

Tarix, Unigene deal

Tarix exercised an option to license exclusive, worldwide rights to Unigene's Peptelligence drug delivery technology for use with angiotensin I-VII and its functional equivalents, analogs and derivatives. Angiotensin is the pharmaceutical ingredient in Tarix's TXA127, a peptide that stimulates...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >